AjayKNookaMD

PubMed

• Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
  Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Vic...> ;Cancer. 2024 Apr 17
• Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
  Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Bad...> ;British Journal of Haematology. 2024 Mar 19
• Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components.
  Wheeler, A., Snyder, E., Refaai, M., Cohn, C., Poisson, J., Fontaine, M., Sehl, M., Nooka, A., Uhl, L., Spinella, P., Fenelus, M., Liles, D., Coyle, T., Becker, J., Je...> ;Blood Advances. 2024 Mar 6
• Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens:...
  Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natal...> ;The Lancet. Haematology. 2024 Mar 1
• Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
  Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura, Jinma Ren, Umberto Conte> ;British Journal of Haematology. 2024 Feb 29
• Shrinking the divide: improving myeloma CART access.
  Ajay K Nooka, Monique A Hartley-Brown, Kenneth C Anderson, Sagar Lonial> ;Blood Advances. 2024 Jan 9
• Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
  Frerichs, K., Verkleij, C., Mateos, M., Martin, T., Rodriguez, C., Nooka, A., Banerjee, A., Chastain, K., Perales-Puchalt, A., Stephenson, T., Uhlar, C., Kobos, R., va...> ;Blood Advances. 2024 Jan 9
• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
  Scott, S., Marin, E., Maples, K., Joseph, N., Hofmeister, C., Gupta, V., Kaufman, J., Lonial, S., Nooka, A., Dhodapkar, M.> ;Blood Cancer Journal. 2023 Dec 20
• Addressing the disparities: the approach to the African American patient with multiple myeloma.
  Bhutani, M., Blue, B., Cole, C., Badros, A., Usmani, S., Nooka, A., Bernal-Mizrachi, L., Mikhael, J.> ;Blood Cancer Journal. 2023 Dec 18
• Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
  Thomas G Martin, Philippe Moreau, Saad Z Usmani, Alfred Garfall, María-Victoria Mateos, Jesús F San-Miguel, Albert Oriol, Ajay K Nooka, Laura Rosinol, Ajai Chari, Lion...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
• 1 citations
  Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
  Ajay K Nooka, Cesar Rodriguez, María Victoria Mateos, Salomon Manier, Katherine Chastain, Arnob Banerjee, Rachel Kobos, Keqin Qi, Raluca Verona, Margaret Doyle, Thomas...> ;Cancer. 2024 Mar 15
• Glücksklee, the Quad, and High-Risk Myeloma.
  Ajay K Nooka, Jonathan L Kaufman, Sagar Lonial> ;Journal of Clinical Oncology. 2024 Jan 1
• Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
  Alberto Moreno, Kelly Manning, Maryam I Azeem, Ajay K Nooka, Madison Ellis, Renee Julia Manalo, Jeffrey M Switchenko, Bushra Wali, Jonathan L Kaufman, Craig C Hofmeist...> ;Research Square. 2023 Sep 21
• 2 citations
  Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
  Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
• 51 citations
  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
  Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince, Ruben Niesvizky, Paula Rodrίguez-Otero, Joaquin Martinez-Lopez, Guenther Koe...> ;Nature Medicine. 2023 Sep 1
• 3 citations
  Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
  M Hope Robinson, Nancy Y Villa, David L Jaye, Ajay K Nooka, Alyssa Duffy, Samuel S McCachren, Julia Manalo, Jeffrey M Switchenko, Sierra Barnes, Sayalee Potdar, Maryam...> ;The Journal of Clinical Investigation. 2023 Aug 1
• 1 citations
  Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multip...
  David J Chung, Nina Shah, Juan Wu, Brent Logan, Lina Bisharat, Natalie Callander, Giulia Cheloni, Kenneth Anderson, Thinle Chodon, Binod Dhakal, Steve Devine, Poorvi S...> ;Clinical Cancer Research. 2023 Dec 1
• 2 citations
  Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
  Laura F Sun, Kathryn T Maples, Kevin H Hall, Yuan Liu, Yichun Cao, Nisha S Joseph, Craig C Hofmeister, Jonathan L Kaufman, Ajay K Nooka, Sagar Lonial, R Donald Harvey,...> ;JCO Oncology Practice. 2023 Sep 1
• Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
  Chloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, Mehmet A Bilen, Taofeek K Owonikoko, Jonathan L Kaufman, Ajay K Nooka, Colleen M Lewis, Elise Hitron, Hannah ...> ;The Oncologist. 2023 Dec 11
• Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
  Philippe Moreau, Niels Wcj van de Donk, Hareth Nahi, Albert Oriol, Ajay K Nooka, Thomas Martin, Laura Rosinol, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, ...> ;Future Oncology. 2023 Apr 1
• 1 citations
  Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
  Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jenn...> ;Journal of Comparative Effectiveness Research. 2023 Jun 1
• Cardiotoxicities of Cellular Therapies: A Practical Approach in a Sea of Uncertainty.
  Ajay K Nooka, Mandawat, A.> ;JCO Oncology Practice. 2023 Jun 1
• 8 citations
  Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multi...
  Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, Arnob Banerjee, Rachel Kobos, Lixia Pei, Ming Qi, Raluca Verona, Margaret Doyle, Jennifer Smit, Weili Sun, Danielle...> ;Cancer. 2023 Jul 1
• 1 citations
  Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
  Kathryn T Maples, Kevin H Hall, Nisha S Joseph, Craig C Hofmeister, Vikas Gupta, Jonathan L Kaufman, Ajay K Nooka, Sagar Lonial, Dhodapkar, M.> ;Blood Cancer Journal. 2023 Feb 20
• A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the G...
  Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Badro...> ;Future Oncology. 2022 Dec 1
• Join now to see all

Abstracts/Posters

• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all